The interactions of antiepileptic drugs in oncology practice;Interacciones de los antiepilépticos en la práctica oncológica

Revista de Neurologia

Volumn 42, Issue 11, 2006, Pages 681-690

  Armijo, Juan A ^a,b   Sanchez M B ^b   Campos, C ^b   Adin J ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiepileptic drugs; Antineoplastic agents; Interactions

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBAMAZEPINE; CISPLATIN; CORTICOSTEROID; CYTOCHROME P450; ETIRACETAM; ETOPOSIDE; FLUOROURACIL; GABAPENTIN; LAMOTRIGINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NITROSOUREA; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TAXANE DERIVATIVE; TENIPOSIDE; TOPIRAMATE; URACIL; VALPROIC ACID; VINCA ALKALOID; ZONISAMIDE;

CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG ELIMINATION; DRUG OVERDOSE; DRUG SUBSTITUTION; EPILEPSY; HUMAN; REVIEW; DRUG INTERACTION; DRUG MONITORING; NEOPLASM; POLYPHARMACY;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; HUMANS; NEOPLASMS; POLYPHARMACY;

EID: 33749834441     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4211.2005656     Document Type: Review

References (97)

1. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995; 52: 717-24.
2. Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol 1996; 9: 424-8.
3. Vecht CJ, Wagner GL, Wilms EB. Treating seizures in patients with brain tumours: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 2003; 30 (Suppl 19): S49-52.
4. Vecht CJ. Clinical management of brain metastasis. J Neurol 1998; 245: 127-31.
5. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; 40: 523-30.
6. Patsalos PN, Froscher W, Pisani F, Van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365-85.
7. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurology 2003; 2: 404-9.
8. Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports. Pharmacotherapy 1998; 18: 1304-7.
9. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999; 66: 589-93.
10. Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27: 221-33.
11. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions: new approaches to brain tumor therapy central nervous system consortium. J Clin Oncol 1997; 15: 3121-8.
12. Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC Jr, Spence AM, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998; 16: 2188-94.
13. Chang SM, Kuhn JG, Robins HI, Schold SC Jr, Spence AM, Berger MS, et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 2001; 9: 417-22.
14. Stocley IH. Interacciones farmacológicas. 1 ed. Barcelona: Pharma Editores, 2004.
15. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, et al. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol 2002; 24: 130-3.
16. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17: 1516-25.
17. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent oligodendriogliomas. J Neurooncol 2002; 59: 157-63.
18. Kuhn JG. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North american brain tumor Consortium preliminary report. Oncology (Huntingt) 2002; 16 (Suppl 7): S33-40.
19. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97: 2381-6.
20. Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewa-Crews KR. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy. Cancer 2003; 97: 2374-80.
21. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003; 9: 2940-9.
22. Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol 2003; 14: 603-14.
23. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998; 4: 783-9.
24. Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants: NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 1998; 42: 118-26.
25. Alderson L, Supko J, Maestri X, Sampath P, Benincasa E, Belonogova N, et al. Phase I/II trial of gimatecan in patients with recurrent malignant glioma. Proc Am Soc Clin Oncol 2003; 22: 104.
26. Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol 2000; 48: 249-50.
27. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000; 356: 285-90.
28. Baker DK, Rodman JH, Pui CH, Rivera GK, Evans WE. Anticonvulsants increase clearance of teniposide. Clin Pharmacol Ther 1991; 49:195.
29. Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 1992; 10: 311-5.
30. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-6.
31. Riggs CE, Engel S, Wesley M, Wiernik PH, Bachur NR. Doxorubicin pharmacokinetics, prochlorperazine and barbiturate effects. Clin Pharmacol Ther 1982; 31: 263.
32. Koranyi L, Gero L. Influence of diphenylhydantoin on the effect of streptozotocin. BMJ 1979; 1: 127.
33. Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma. N Engl J Med 1972; 286: 1125-8.
34. Chalk JB, Ridgeway K, Brophy T, Yelland JD, Eadie MJ. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984; 47: 1087-90.
35. Gambertoglio JG, Holford NH, Kapusnik JE, Nishikawa R, Saltiel M, Stanik-Lizak P, et al. Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 1984; 25: 119-23.
36. Haque N, Thrasher K, Werk EE Jr, Knowles HC Jr, Sholiton LJ. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J Clin Endocrinol Metab 1972; 34: 44-50.
37. McLelland J, Jack W. Phenytoin/dexamethasone interaction: a clinical problem. Lancet 1978; 1: 1096-7.
38. Brooks PM, Buchanan WW, Grove M, Downie WW. Effects of enzyme induction on metabolism of prednisolone: clinical and laboratory study. Ann Rheum Dis 1976; 35: 339-43.
39. Wassner SJ, Pennisi AJ, Malekzadeh MH, Fine RN. The adverse effect of anticonvulsant therapy on renal allograft survival: a preliminary report. J Pediatr 1976; 88: 134-7.
40. Prados M, Chang S, Burton E, Kapadia A, Rabbitt J, Page M, et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc Am Soc Clin Oncol 2003; 33: 99.
41. Prados M, Yung P, Wen L, Junck L, Fink K, Cloughesy T, et al. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North american brain tumor consortium. J Clin Oncol 2004; 22: 1504.
42. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitrosourea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 2001; 12: 217-9.
43. Prough RA, Coomes MW, Cummings SW, Wiebkin P. Metabolism of procarbazine. Adv Exp Med Biol 1981; 136: 983-96.
44. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997; 62: 225-9.
45. Ghosn M, Carde P, Leclerq B, Flamant F, Friedman S, Droz JP, et al. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer 1988; 75: 391-2.
46. Armijo JA, Adín J. Bases farmacocinéticas para la asociación de antiepilépticos. Rev Neurol 1997; 25 (Supl 4): S382-95.
47. Hansten PD, Horn JT. Hansten and Horn's drug interactions analysis and management: a clinical perspective and analysis of current developments. St. Louis: Facts & Comparison; 2004.
48. Fischer JH. Drug interactions with antiepileptic agents. CNS News 2004; 6: 85-95.
49. Silvester RK, Lewis FB, Caldwell KC, Lobell M, Perry R, Sawchuk RA. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 1986; 6: 302-5.
50. Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacother 1996; 30: 520-6.
51. Bollini P, Riva R, Albani F, Ida N, Cacciari L, Bollini C, et al. Decreased phenytoin level during antineoplastic therapy: a case report. Epilepsia 1983; 24:75-8.
52. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving hemotherapy. Am J Med 1989; 87: 505-10.
53. Ghosh C, Lazarus HM, Hewlett JS, Creger RJ. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neurooncol 1992; 12: 25-32.
54. Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA. Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. Ther Drug Monit 1984; 6: 302-5.
55. Neef C, De Voogd-Van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43: 372-5.
56. Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-Reiche H, Smit EF, Postmus PE. Decreased phenytoin level after carboplatin treatment. Am J Med 1990; 89: 247-8.
57. Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M. Phenytoin-dexamethasone: a possible drug-drug interaction. JAMA 1985; 254: 2062-3.
58. Lackner TE. Interaction of dexamethasone with phenytoin. Pharmacotherapy 1991; 11: 344-7.
59. Nahum MP, Ben Arush MW, Robinson E. Reduced plasma carbamazepine level during chemotherapy in a child with malignant lymphoma. Acta Paediatr Scand 1990; 79: 873-5.
60. Schroder H, Ostergaard JR. Interference of high-dose methotrexate in the metabolism of valproate? Pediatr Hematol Oncol 1994; 11: 445-9.
61. Wakisaka S, Shimauchi M, Kaji Y, Nonaka A, Kinoshita K. Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi 1990; 81: 192-6.
62. Hara T, Ichimiya A. Acute phenytoin intoxication caused by drug interaction with an antitumour agent, tegafur. 20th Japanese Conference in Epilepsia. Tokyo, 1986.
63. Gilbar PJ, Brodribb TR. Phenytoin and fluorouracil interaction. Ann Pharmacother 2001; 35: 1367-70.
64. Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer 2003; 89: 615-6.
65. Konishi H, Morita K, Minouchi T, Nakajima M, Matsuda M, Yamaji A. Probable metabolic interaction of doxifluridine with phenytoin. Ann Pharmacother 2002; 36: 831-4.
66. Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 1995; 36: 513-5.
67. Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB. Phenytoin- dexamethasone interaction: a previously unreported observation. Surg Neurol 1981; 16: 23-4.
68. Irlbacher K, Brandt SA, Meyer BU. In vivo study indicating loss of inhibition in tumour-associated epilepsy. Ann Neurol 2002; 52: 119-22.
69. Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implications for treatment revised. Epilepsia 2003; 44: 1123-32.
70. Hildebrand J. Management of epileptic seizures. Curr Opin Oncol 2004; 16: 314-7.
71. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci 1996; 23: 128-31.
72. Wagner GL, Wilms EB, Van Donselaar CA, Vecht CJ. Levetiracetam: preliminary experience in patients with primary brain tumors. Seizure 2003; 12: 585-6.
73. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301: 7-14.
74. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003; 307: 262-7.
75. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22-31.
76. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42: 1501-6.
77. Newman MJ, Dixon R, Toyonaga B. OC144-093, a novel P glycoprotein inhibitor for the enhancement of antiepileptic therapy. Novartis Found Symp 2002; 243: 213-26.
78. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005; 128: 7-17.
79. Olsen JH, Boice JD, Jensen JP, Fraumeni JF. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 1989; 81: 803-8.
80. Gurney JG, Mueller BA, Preston-Martin S, McDaniel AM, Holly EA, Pogoda JM, et al. A study of pediatric brain tumors association with epilepsy and anticonvulsant use. Neuroepidemiology 1997; 16: 248-55.
81. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone desacetylases. Ann Hematol 2004; 83: 91-2.
82. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of mielodysplatic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-9.
83. Driever HP, Knupfer M, Cinatl J, Wolf J. Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 1999; 211: 323-8.
84. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004; 45: 737-44.
85. Miccoli L, Poirson-Bichat F, Sureau F, Bras-Goncalves R, Bourgeois Y, Dutrillaux B, et al. Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 1998; 90: 1400-6.
86. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiform. J Neurooncol 2003; 63: 81-6.
87. Borg MF, Probert JC, Zwi LJ. Is phenytoin contraindicated in patients receiving cranial irradiation?. Australian Radiol 1995; 39: 42-6.
88. Romero-Maldonado N, Sendra-Tello J, Raboso-García Baquero E, Castaño A. Anticonvulsant hypersensitivity síndrome with fatal outcome. Eur J Dermatol 2002; 12: 503-5.
89. Camartin C, Reinhart WH, Kuhn M. Brain irradiation and phenytoin: a dangerous liaison?. Schweiz Rundsch Med Prax 2003; 92: 393-6.
90. Lisker-Melman M, Hoofnagle JH. Phenytoin hepatotoxicity masked by corticosteroids. Arch Intern Med 1989; 149: 1196-7.
91. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 2004; 22: 427-35.
92. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality standards subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1886-93.
93. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002; 16: 325-38.
94. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol 2002; 14: 299-307.
95. Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, et al., Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003; 30: 106-12.
96. Mason WP. Anticonvulsant prophylaxis for patients with brain tumours: insights from clinical trials. Can J Neurol Sci 2003; 30: 89-90
97. Van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer 2003; 39: 2114-20.